Pharma Penny Stocks Under Rs 100

The table below shows Pharma Penny Stocks Under Rs 100 based on the Highest Market Capitalization.

What Are Pharma Penny Stocks?

Pharma penny stocks in the Indian stock market are shares of small pharmaceutical companies priced below Rs 100. These stocks are highly speculative and involve significant risk due to their low market capitalization and potential for high volatility.

Investing in these stocks can be enticing due to the potential for substantial returns if a company succeeds in breakthrough developments or regulatory approvals. However, the risk of losing the entire investment is also considerably higher compared to more stable stocks.

Investors interested in pharma penny stocks should perform extensive due diligence, focusing on the company’s drug pipeline, market potential, and financial health. Understanding regulatory environments and market dynamics within India is crucial for assessing these investments.

Top 10 Pharma Penny Stocks Under Rs 100

The table below shows the Top 10 Pharma Penny Stocks Under Rs 100 based on 1 Year Return. 

Pharma Penny Stocks Under Rs 100 In India

The table below shows Pharma Penny Stocks Under Rs 100 In India based on 1 Month Return. 

Best Pharma Penny Stocks Under Rs 100

The table below shows the Best Pharma Penny Stocks Under Rs 100 based on the highest day Volume.

List Of Best Pharma Penny Stocks Under Rs. 100

The table below shows a List Of The Best Pharma Penny Stocks Under Rs. 100 based on PE Ratio.

Who Should Invest In Pharma Penny Stocks Under Rs 100?

Investors who should consider pharma penny stocks under Rs 100 are those with high-risk tolerance, speculative investment strategies, and a thorough understanding of the pharmaceutical industry. Such investors must be prepared for significant volatility and the potential for both high returns and substantial losses.

How To Invest In The Pharma Penny Stocks Under Rs 100?

To invest in pharma penny stocks under Rs 100, research and select potential companies with promising pipelines or technologies. Use a reliable broker to buy shares, diversify your portfolio to mitigate risk, and stay updated on pharmaceutical industry news and regulatory changes affecting these stocks.

Performance Metrics Of Pharma Penny Stocks Under Rs 100

The performance metrics of pharma penny stocks under Rs 100 can be highly volatile, reflecting the speculative nature of these investments. Key indicators include share price fluctuations, trading volume, and financial health metrics such as earnings per share and revenue growth.

Investors should also consider the success rates of clinical trials, FDA approvals, and partnership developments as performance indicators. These metrics provide insights into a company’s potential to succeed in the competitive pharmaceutical market, impacting stock performance significantly.

Benefits Of Investing In Pharma Penny Stocks Under Rs 100

The main benefit of investing in pharma penny stocks under Rs 100 is the potential for high returns. These stocks often represent small companies that can experience significant growth if they achieve breakthroughs or gain regulatory approvals.

• High Return Potential: Pharma penny stocks can yield substantial profits if the company successfully brings a new drug to market or partners with larger pharmaceutical firms. Such events can dramatically increase a stock’s value overnight.
• Low Entry Cost: With shares priced under Rs 100, these stocks allow investors to buy a larger quantity of shares with a smaller initial investment, potentially maximizing gains if the stock value increases.
• Market Movements: These stocks are sensitive to market news and regulatory events, offering opportunities for quick gains from market reactions to positive news such as successful drug trials or government approvals.
• Diversification: Adding pharma penny stocks to a diversified investment portfolio can provide a balance to more stable investments. It introduces a higher-risk, higher-reward component that could yield returns uncorrelated with the broader market.
• Innovative Exposure: Investing in these stocks offers exposure to innovative medical research and potential breakthrough treatments that could revolutionize health care and generate significant financial returns if successful.

Challenges Of Investing In Pharma Penny Stocks Under Rs 100

The main challenges of investing in pharma penny stocks under Rs 100 include high volatility, limited liquidity, and significant regulatory risks. Additionally, these stocks often suffer from a lack of information and a higher potential for fraud, making them risky investments.

• High Volatility: Pharma penny stocks under Rs 100 are extremely volatile. Their prices can swing wildly based on news or market sentiment, making them unpredictable and increasing the risk of substantial losses for investors not prepared for such fluctuations.
• Limited Liquidity: These stocks often have lower trading volumes, which can make it difficult to buy or sell large quantities without affecting the stock price. This lack of liquidity can be a significant barrier when trying to exit positions at favorable prices.
• Regulatory Risks: The pharmaceutical industry is heavily regulated. Delays in drug approval processes or negative results from clinical trials can severely impact the stock’s value. Investors must be mindful of the regulatory environment and its potential effects.
• Lack of Information: Small pharmaceutical companies under Rs 100 often lack the visibility of larger companies. This scarcity of information can make it challenging for investors to perform thorough due diligence, assess the company’s potential, and make informed investment decisions.
• Fraud and Mismanagement Risk: The lower levels of scrutiny and oversight in smaller, less-regulated companies can lead to higher risks of fraud or mismanagement. Investors may face challenges in verifying the authenticity of the company’s claims and the integrity of its management.

Introduction To Pharma Penny Stocks Under Rs 100

Syncom Formulations (India) Ltd

The Market Cap of Syncom Formulations (India) Ltd is ₹1,506.82 crore. The stock’s 1-month return is -15.39%, while its 1-year return is 5.04%. It is currently 33.33% away from its 52-week high.

Syncom Formulations (India) Ltd is a pharmaceutical company that specializes in the manufacturing and distribution of a wide range of generic medicines. The company focuses on producing high-quality, affordable medications, catering to both domestic and international markets. With a diverse portfolio spanning tablets, capsules, syrups, and injectables, Syncom has established a strong presence in the healthcare sector. Its commitment to research and development allows it to introduce innovative formulations, ensuring it remains competitive in the evolving pharmaceutical landscape.

The company has a significant market presence due to its cost-effective production processes and strategic expansion plans. Syncom’s exports to global markets have helped drive growth, despite fluctuations in stock performance. The stock has seen a decline in its monthly return but has managed to post positive one-year growth. However, it remains significantly below its 52-week high, indicating room for potential recovery. Investors continue to monitor the company’s performance closely as it navigates market challenges.

Gennex Laboratories Ltd

The Market Cap of Gennex Laboratories Ltd is ₹295.68 crore. The stock’s 1-month return is -13.46%, while its 1-year return is -32.75%. It is currently 11.74% away from its 52-week high.

Gennex Laboratories Ltd is a pharmaceutical company engaged in the production of active pharmaceutical ingredients (APIs) and intermediates. The company has built a reputation for supplying high-quality products to both domestic and international markets. With a focus on research and development, Gennex aims to strengthen its portfolio by introducing innovative and cost-effective solutions to meet global healthcare needs. The company’s commitment to stringent quality standards and regulatory compliance has helped it establish strong business relationships with industry partners.

Despite its strong operational foundation, the stock has experienced notable declines in recent months, reflecting broader market trends and industry challenges. Its one-year return has been significantly negative, indicating a tough period for investors. However, with its strategic initiatives and expansion efforts, the company is looking to regain momentum. The stock remains within reach of its 52-week high, suggesting potential upside if market conditions improve and investor sentiment turns positive.

Vaishali Pharma Ltd

The Market Cap of Vaishali Pharma Ltd is ₹149.85 crore. The stock’s 1-month return is -18.17%, while its 1-year return is -8.87%. It is currently 9.85% away from its 52-week high.

Vaishali Pharma Ltd is a leading pharmaceutical company involved in the marketing, manufacturing, and distribution of a wide range of healthcare products. The company specializes in formulations, nutraceuticals, APIs, and veterinary products, catering to a broad customer base across India and international markets. With a focus on quality and innovation, Vaishali Pharma has built a strong reputation in the industry. It continuously invests in research and development to enhance its product portfolio and expand its market presence.

Despite its strong fundamentals, the stock has faced a downturn in its monthly and yearly returns, reflecting industry-wide challenges and market volatility. However, with its diversified product offerings and strategic partnerships, Vaishali Pharma remains well-positioned for future growth. Investors are closely watching the company’s ability to navigate market conditions and capitalize on opportunities in the healthcare sector.

Ajooni Biotech Ltd

The Market Cap of Ajooni Biotech Ltd is ₹129.01 crore. The stock’s 1-month return is 1.10%, while its 1-year return is 31.92%. It is currently 65.51% away from its 52-week high.

Ajooni Biotech Ltd is a biotechnology and animal nutrition company engaged in the production of high-quality animal feed supplements and veterinary healthcare products. The company focuses on providing innovative and cost-effective solutions to enhance livestock productivity and well-being. With a strong emphasis on research and development, Ajooni Biotech has introduced several breakthrough products, gaining recognition in the agribusiness and veterinary sectors.

Despite its positive long-term growth, the stock remains significantly below its 52-week high, indicating potential volatility. The company’s ability to sustain growth depends on continued innovation and expanding its customer base. Investors remain optimistic about its long-term potential, given the rising demand for animal nutrition products.

Lasa Supergenerics Ltd

The Market Cap of Lasa Supergenerics Ltd is ₹113.25 crore. The stock’s 1-month return is -16.16%, while its 1-year return is -32.99%. It is currently 1.58% away from its 52-week high.

Lasa Supergenerics Ltd specializes in the manufacturing of veterinary APIs and pharmaceutical products. The company is known for its expertise in the synthesis of specialty chemicals and intermediates used in the veterinary and pharmaceutical industries. Its robust research and development capabilities have helped it establish a strong market presence.

The stock has witnessed a decline in both its monthly and yearly returns, reflecting market challenges. However, with its focus on innovation and a growing demand for specialty APIs, Lasa Supergenerics remains optimistic about future growth prospects. Investors are closely monitoring its market strategy and expansion plans.

Remedium Lifecare Ltd

The Market Cap of Remedium Lifecare Ltd is ₹112.90 crore. The stock’s 1-month return is -38.57%, while its 1-year return is -91.55%. It is currently 0% away from its 52-week high.

Remedium Lifecare Ltd is a pharmaceutical company engaged in the production and distribution of medicines for various therapeutic applications. The company emphasizes quality and affordability, catering to a growing demand for essential medicines. With a commitment to innovation, it continues to expand its product offerings in both domestic and international markets.

Despite a sharp decline in stock performance, the company remains focused on strengthening its market position. The pharmaceutical sector’s growth potential provides a long-term opportunity for Remedium Lifecare, although short-term volatility remains a concern for investors.

Achyut Healthcare Ltd

The Market Cap of Achyut Healthcare Ltd is ₹85.27 crore. The stock’s 1-month return is -20.92%, while its 1-year return is -19.82%. It is currently 13.80% away from its 52-week high.

Achyut Healthcare Ltd operates in the pharmaceutical sector, specializing in the manufacturing and distribution of healthcare and wellness products. The company focuses on providing high-quality medicines across multiple therapeutic categories, ensuring accessibility and affordability. With a strong commitment to innovation and research, Achyut Healthcare continues to develop new formulations that cater to emerging healthcare needs.

Despite facing significant declines in both short-term and long-term stock performance, the company remains well-positioned for growth due to its focus on expansion and product diversification. The stock is still relatively close to its 52-week high, suggesting potential for recovery if market sentiment improves. Investors are keeping a close watch on the company’s financial performance and strategic initiatives in the coming months.

Ind Swift Ltd

The Market Cap of Ind Swift Ltd is ₹79.57 crore. The stock’s 1-month return is -22.19%, while its 1-year return is -25.58%. It is currently 3.94% away from its 52-week high.

Ind Swift Ltd is a well-established pharmaceutical company known for its expertise in developing and manufacturing a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company has a strong presence in both domestic and international markets, leveraging its state-of-the-art production facilities and research-driven approach. With a focus on quality and regulatory compliance, Ind Swift has built a reputable brand in the healthcare sector.

Despite its solid fundamentals, the company’s stock has faced considerable declines over the past year, reflecting broader market trends and industry challenges. However, with its continued efforts in expansion and innovation, there is potential for a turnaround. Investors remain cautiously optimistic, closely monitoring the company’s growth strategies and market performance.

Welcure Drugs and Pharmaceuticals Ltd

The Market Cap of Welcure Drugs and Pharmaceuticals Ltd is ₹74.82 crore. The stock’s 1-month return is -29.49%, while its 1-year return is 51.91%. It is currently 90.69% away from its 52-week high.

Welcure Drugs and Pharmaceuticals Ltd is engaged in the production of pharmaceutical formulations, catering to both domestic and international markets. The company has a strong focus on research and development, ensuring that it delivers high-quality and innovative products. Its commitment to regulatory compliance and strict quality standards has helped establish a strong brand presence in the industry.

Despite posting an impressive one-year return, the stock remains significantly below its 52-week high, indicating potential volatility. Investors are closely watching the company’s financial performance and market strategies to determine future growth prospects. With the pharmaceutical industry witnessing increasing demand, Welcure Drugs has opportunities for expansion, provided it successfully navigates market challenges.

Vista Pharmaceuticals Ltd

The Market Cap of Vista Pharmaceuticals Ltd is ₹60.51 crore. The stock’s 1-month return is -2.37%, while its 1-year return is -30.20%. It is currently 9.23% away from its 52-week high.

Vista Pharmaceuticals Ltd is a pharmaceutical company specializing in the development and production of generic medications. With a focus on cost-effective and high-quality healthcare solutions, the company supplies its products to domestic and global markets. Its expertise in research and regulatory compliance ensures that it meets international quality standards.

Despite a relatively stable short-term performance, the stock has experienced a significant decline over the past year, reflecting broader industry challenges. However, the company’s strong product portfolio and commitment to innovation position it for potential recovery. Investors are keeping an eye on its expansion strategies and financial health to assess future growth prospects.

Top 10 Pharma Penny Stocks Under Rs  100- FAQs

Here are some of the Best Stock Research Articles listed based on Top Sectors (Industries), Market Cap, and Fundamental Analysis Factors:

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.